Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NDRA

ENDRA Life Sciences (NDRA)

ENDRA Life Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NDRA
DateTimeSourceHeadlineSymbolCompany
20/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
20/05/202422:00Business WireENDRA Provides Update Following In-person Meeting with FDANASDAQ:NDRAENDRA Life Sciences Inc
15/05/202406:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
15/05/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
15/05/202406:05Business WireENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
11/05/202407:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
11/05/202407:17Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NDRAENDRA Life Sciences Inc
07/05/202422:00Business WireENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NDRAENDRA Life Sciences Inc
02/05/202422:00Business WireENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsNASDAQ:NDRAENDRA Life Sciences Inc
29/03/202407:05Business WireENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
21/03/202423:00Business WireENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024NASDAQ:NDRAENDRA Life Sciences Inc
28/02/202400:00Business WireENDRA Life Sciences Installs First TAEUS System in the UKNASDAQ:NDRAENDRA Life Sciences Inc
24/02/202409:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NDRAENDRA Life Sciences Inc
22/02/202400:00Business WireNew ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS SystemNASDAQ:NDRAENDRA Life Sciences Inc
15/02/202400:30Business WireENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and EuropeNASDAQ:NDRAENDRA Life Sciences Inc
30/12/202309:07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NDRAENDRA Life Sciences Inc
30/11/202300:00Business WireENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System TechnologyNASDAQ:NDRAENDRA Life Sciences Inc
28/11/202300:00Business WireENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor ConferenceNASDAQ:NDRAENDRA Life Sciences Inc
15/11/202308:05Business WireENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
15/11/202308:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
09/11/202300:00Business WireENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New PatentsNASDAQ:NDRAENDRA Life Sciences Inc
08/11/202308:05Business WireENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:NDRAENDRA Life Sciences Inc
07/11/202300:00Business WireENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023NASDAQ:NDRAENDRA Life Sciences Inc
07/09/202322:00Business WireAbstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023NASDAQ:NDRAENDRA Life Sciences Inc
30/08/202322:00Business WireENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDANASDAQ:NDRAENDRA Life Sciences Inc
23/08/202322:00Business WireENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European PatentsNASDAQ:NDRAENDRA Life Sciences Inc
15/08/202306:53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NDRAENDRA Life Sciences Inc
15/08/202306:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
15/08/202306:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
15/08/202306:05Business WireENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:NDRA